Quisovalimab - CAS 2427667-03-4

Quisovalimab (AVTX-002; AEVI 002; SAR 252067), a human monoclonal antibody targeting LIGHT, a tumor necrosis factor (TNF) -related cytokine (TNFSF14), is crucial for managing acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) in COVID-19 and has potential applications in treating ARDS related to COVID-19, subject to ongoing research [1].

SARS-CoV

Microbiology/Virology

2427667-03-4

-20°C

Ice Packs

Inhibitory Antibodies